L7R Stock Overview
A pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Lipidor AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0044 |
| 52 Week High | SEK 0.17 |
| 52 Week Low | SEK 0.0002 |
| Beta | 0.39 |
| 11 Month Change | -68.57% |
| 3 Month Change | -89.22% |
| 1 Year Change | -97.33% |
| 33 Year Change | -99.71% |
| 5 Year Change | n/a |
| Change since IPO | -99.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| L7R | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1,000.0% | -3.3% | 0.9% |
| 1Y | -97.3% | -18.9% | 3.0% |
Return vs Industry: L7R underperformed the German Pharmaceuticals industry which returned -17% over the past year.
Return vs Market: L7R underperformed the German Market which returned 3.9% over the past year.
Price Volatility
| L7R volatility | |
|---|---|
| L7R Average Weekly Movement | 2,062.2% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: L7R's share price has been volatile over the past 3 months.
Volatility Over Time: L7R's weekly volatility has increased from 1031% to 2062% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 5 | Ola Holmlund | lipidor.se |
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine.
Lipidor AB (publ) Fundamentals Summary
| L7R fundamental statistics | |
|---|---|
| Market cap | €127.28k |
| Earnings (TTM) | -€1.03m |
| Revenue (TTM) | €159.14k |
0.8x
P/S Ratio-0.1x
P/E RatioIs L7R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L7R income statement (TTM) | |
|---|---|
| Revenue | SEK 1.80m |
| Cost of Revenue | SEK 7.48m |
| Gross Profit | -SEK 5.68m |
| Other Expenses | SEK 5.91m |
| Earnings | -SEK 11.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -315.97% |
| Net Profit Margin | -644.96% |
| Debt/Equity Ratio | -5.8% |
How did L7R perform over the long term?
See historical performance and comparison